8-K

0000950170-24-027585.txt : 20240307 0000950170-24-027585.hdr.sgml : 20240307 20240307070907 ACCESSION NUMBER: 0000950170-24-027585 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240305 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 24728140 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 8-K 1 alks-20240305.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 5, 2024

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)


Ireland		001-35299				98-1007018
(State or other jurisdiction		(Commission				(IRS Employer
of incorporation)		File Number)				Identification No.)


Connaught House, 1 Burlington Road
Dublin 4, Ireland D04 C5Y6
(Address of principal executive offices)

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, $0.01 par value		ALKS		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Effective March 5, 2024, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to eleven (11) directors and elected Nancy S. Lurker to the Board, with an initial term expiring at the Company’s 2024 annual general meeting of shareholders (the “2024 Annual Meeting”). As of the date of this Current Report on Form 8-K, Ms. Lurker has not been appointed to any committee of the Board.

For her service on the Board, Ms. Lurker will receive (i) a new director equity grant and (ii) an annual cash retainer and annual equity grant, in each case with the terms, and in the amounts, as determined in accordance with the processes described in the “Director Compensation” section of the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on May 25, 2023. The new director equity grant and a prorated annual equity grant for the 12-month period ending at the 2024 Annual Meeting will each be granted to Ms. Lurker in April 2024, on the date of the Company’s monthly new hire employee grant date. A prorated portion of the new director equity grant will be subject to forfeiture in the event that Ms. Lurker is not re-elected to the Board by the Company’s shareholders at the 2024 Annual Meeting.

In addition, the Company will enter into a deed of indemnification with Ms. Lurker in substantially the form filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 29, 2020, and Alkermes, Inc., a wholly-owned indirect subsidiary of the Company, will enter into an indemnification agreement with Ms. Lurker in substantially the form filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 29, 2020.

Ms. Lurker is not, nor has been since January 1, 2023, a participant in any transaction involving the Company, or a participant in any proposed transaction with the Company, in each case, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On March 7, 2024, the Company issued a press release announcing Ms. Lurker’s appointment to the Board, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX


Exhibit No.		Description

99.1		Press release issued by Alkermes plc dated March 7, 2024.
104		Cover page interactive data file (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ALKERMES PLC

Date: March 7, 2024	By:		/s/ David J. Gaffin
			David J. Gaffin
			Secretary

3

EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1



	Alkermes Contacts:
	For Investors:	Sandy Coombs +1 781 609 6377
	For Media:	Katie Joyce +1 781 249 8927

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

DUBLIN, March 7, 2024 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company’s Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches.

“Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, governance, strategic planning, product development and commercialization. This broad expertise will be an important asset to the Board and the company as we drive continued growth of our existing portfolio of proprietary products, expand our portfolio and bring new products to market,” said Richard Pops, Chief Executive Officer of Alkermes. “Nancy’s appointment reflects the Board’s ongoing commitment to robust board refreshment and diversity and to the importance of aligning the qualifications and experience of our directors with our strategy and growth opportunities. We welcome Nancy to the Board and look forward to working together.”

“I am delighted to join Alkermes’ Board and to work with the management team as the company continues to advance its important work to bring innovative medicines to patients living with serious neurological and psychiatric conditions,” said Ms. Lurker. “I look forward to sharing my insights and supporting the company as it continues to advance its strategy and builds upon its position as a leader in the field of neuroscience.”

About Nancy Lurker

Ms. Lurker most recently served as Chief Executive Officer of EyePoint Pharmaceuticals, Inc., a publicly-traded specialty biopharmaceutical company, from 2016 to July 2023, at which time she transitioned to her current role as Executive Vice Chair of EyePoint Pharmaceuticals’ board of directors. She also served as President of EyePoint Pharmaceuticals from 2016 to January 2023. Prior to EyePoint Pharmaceuticals, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc. (now INterpace Diagnostics Group, Inc.), a publicly-traded healthcare commercialization company, and as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. Prior to that, Ms. Lurker held various senior positions at other leading

1

pharmaceutical companies including Pharmacia Corporation (now a part of Pfizer, Inc.), ImpactRx and Bristol-Myers Squibb Company.

Ms. Lurker currently serves on the board of directors of EyePoint Pharmaceuticals, Altasciences, LLC, a private contract research organization and National Sanitation Foundation, a not-for-profit organization dedicated to improving human health through quality standards. She previously served on the boards of directors of the Cancer Treatment Centers of America, and current and formerly publicly-traded companies Aquestive Therapeutics, Inc., X4 Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Mallinckrodt plc, PDI, Inc., Elan Corporation, plc, and ConjuChem Biotechnologies. Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

About Alkermes plc

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including its ability to drive continued growth of its proprietary products, expand its portfolio and bring new products to market; and the potential therapeutic, clinical and commercial value of the company’s investigational and commercial products. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2023 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the

2

date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

###

3

EX-101.SCH 3 alks-20240305.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Entity Address, Country Entity Address, Country Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 05, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 05, 2024
Entity Registrant Name	Alkermes plc.
Entity Central Index Key	0001520262
Entity Emerging Growth Company	false
Entity File Number	001-35299
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1007018
Entity Address, Address Line One	Connaught House
Entity Address, Address Line Two	1 Burlington Road
Entity Address, City or Town	Dublin 4
Entity Address, Country	IE
Entity Address, Postal Zip Code	D04 C5Y6
City Area Code	353
Local Phone Number	1-772-8000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Ordinary shares, $0.01 par value
Trading Symbol	ALKS
Security Exchange Name	NASDAQ

EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alks-20240305.htm alks-20240305.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alks-20240305.htm": { "nsprefix": "alks", "nsuri": "http://www.alkermes.com/20240305", "dts": { "inline": { "local": [ "alks-20240305.htm" ] }, "schema": { "local": [ "alks-20240305.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_92028c65-1ac1-464b-868e-f94fadb8a2d6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "alks-20240305.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_92028c65-1ac1-464b-868e-f94fadb8a2d6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "alks-20240305.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "verboseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "verboseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.alkermes.com/20240305/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-027585-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-027585-xbrl.zip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end XML 15 alks-20240305_htm.xml IDEA: XBRL DOCUMENT 0001520262 2024-03-05 2024-03-05 false 0001520262 Alkermes plc. 8-K 2024-03-05 L2 001-35299 98-1007018 Connaught House 1 Burlington Road Dublin 4 IE D04 C5Y6 353 1-772-8000 false false false false Ordinary shares, $0.01 par value ALKS NASDAQ false